#6 Newsletter – JP Jenkins
Sixth Edition
No Summer Holidays Here.
This month we announced another new client – Superdry (Well done to all the team), alongside this we saw the announcements from Sondrel, i(x) Net Zero and Destiny Pharma Limited who intend to join JPJ very soon.
We are delighted to announce the following new admissions to JP Jenkins:
Superdry PLC (JPJ: SDRY)
Superdry announced its shares have been admitted to trade on JP Jenkins. Superdry plc designs, produces, markets, and sells clothing, footwear, and accessories primarily under the Superdry brand for men and women in the United Kingdom and internationally. It operates through Retail and Wholesale segments. The Company operates through stores, concessions, various Internet sites, multi-brand independents and distributors, franchise, and license stores.It operates 213 owned, and 410 franchised and licensed stores; and 18 international websites. The company was formerly known as SuperGroup Plc and changed its name to Superdry plc in January 2018. Superdry plc was founded in 1985 and is headquartered in Cheltenham, the United Kingdom.
Julian Dunkerton, Co-Founder & CEO of Superdry PLC said,
“Today’s delisting from the London stock market marks an important milestone in our journey back to sustainable long-term growth. We are confident that life away from the markets will allow us to make decisions more quickly and focus on doing what we do best: creating quality clothes that serves our diverse community, prioritises sustainability, leads with craft, and celebrates culture. We are now well-placed to build on our strengths as a great British brand renowned globally for quality, craftsmanship, and authenticity. I am incredibly grateful to all who have supported us so far.”
Veronika Oswald, Commercial Director of JP Jenkins Ltd commented:
“Overall, SuperDry Plc’s shift to JP Jenkins underscores a broader trend where companies are exploring new venues and methods to meet their trading and shareholder engagement needs. This transition is paving the way for other companies considering similar moves, fostering a dynamic and adaptive trading environment in London.”
The indicative pricing for the ordinary shares (ISIN: GB00B60BD277), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/).
To read more, please see the full EQS below:https://lnkd.in/eaR2t4b9
Destiny Pharma (AIM:DEST)
Announced its intentions to join JP Jenkins to trade its ord shares, post the AGM if approved. Please see the full RNS below:
Sondrel (AIM:SND)
Announced its intentions to join JP Jenkins to trade its ord shares, post the AGM if approved. Please see the full RNS below:
https://ir.sondrel.com/investors/news/archive/2024/220724
Issuer news – Check out the latest updates and news from our clients:
Cafédirect PLC (JPJ: CDR):
Cafe Direct recently released Progress Report. In 2023, they doubled in size overnight with the purchase of Bewley’s UK. One new roastery. Two new coffee brands. Hundreds of venues selling our coffee across the UK. Millions of farmers earning enough to feed their families. Take a look at some of their highlights from last year below.
Read the full report here: https://lnkd.in/eGEci-kK
e-therapeutics PLC (JPJ: ETX):
Earlier this month, e-therapeutics PLC announced its completion of a £28.9Million fundraise.
e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased to announce that it has completed its £28.90 million fundraise by way of a subscription by funds managed by M&G Investment Management Limited and Richard Griffiths and his controlled undertakings, both existing shareholders of the Company. The Subscription by M&G was conditional upon clearance under the National Security and Investment Act 2021, which is now complete.
To read more, please see the full EQS below:https://lnkd.in/emAfSZzf
Redx Pharma (JPJ: RED):
Redx Pharma released their latest update – “Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers”
To read the full report, please click the link below: https://lnkd.in/e2GY6BpJNatalie
Liquidity Lens UK Business Angels Association
Our Head of Corporate Mason Doick took part in a Friday Focus session webinar with UKBAA to discuss – ‘Are secondary markets a pathway to Liquidity for Early-Stage Investors?’.
With first-time funding rounds at an all-time low, early-stage investors are increasingly seeking exits so that they can recycle capital back into the UK’s high-potential innovators.
It was a very enjoyable and interesting session, with tens of questions from the 60+ audience that attended the live seminar. The recording is on the UKBAA centre of excellence for their members.
UKBAA Annual Awards Dinner
Some of the JP Jenkins team attended the UKBAA awards this year, delighted to meet and catch up with friendly faces from across the industry in capital markets and the private sphere.
Well done to all the winners and runners up!
CISI events:
JP Jenkins took part in a three part series with CISI talking all things liquidity. Last week was our last session with them, focusing on the admission process for Issuers / companies joining the platform and the importance of ESG / Investor Relations featuring Veronika Oswald (Commercial Director at JP Jenkins).
Charity:
Last week our team here at JP Jenkins, helped with donating prizes to a sponsored charity raffle, raising over £700, to raise funds for Glasgow Children’s Hospital Charity.
Learning 101 with JP Jenkins – Check out our latest videos here on:
As always, if you want to learn more about JP Jenkins – please check out the videos below or contact our team on 0207 469 0937 or email info@jpjenkins.com
Want to keep up to date with our companies?
Subscribe to our newsletter and receive latest information on your favourite companies and JP Jenkins news.
